ABIO
NASDAQARCA biopharma Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Latest news
25 items- 13D/GAmendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
- INSIDERDirector Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- 13D/GSEC Form SC 13D filed by ARCA biopharma Inc.SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)
- INSIDERNew insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERNew insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kulkarni Samarth3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dambkowski Carl3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ball Kristine M3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quinlan Paul T3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Goncalves Joana3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Agarwal Arjun3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERNew insider Klein Lawrence Otto claimed ownership of 852,338 shares (SEC Form 3)3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECARCA biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERSEC Form 4 filed by See footnote 1 Ma-Weaver Jacob4 - ARCA biopharma, Inc. (0000907654) (Issuer)
- PRARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitWESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with
- SECSEC Form 425 filed by ARCA biopharma Inc.425 - ARCA biopharma, Inc. (0000907654) (Subject)
- SECARCA biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ARCA biopharma, Inc. (0000907654) (Filer)
- PRARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsWESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special
- SECARCA biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - ARCA biopharma, Inc. (0000907654) (Filer)
- PRARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka TherapeuticsWESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of
- SECSEC Form 425 filed by ARCA biopharma Inc.425 - ARCA biopharma, Inc. (0000907654) (Subject)
- SECARCA biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ARCA biopharma, Inc. (0000907654) (Filer)
- PRARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka TherapeuticsSpecial dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors has declared a special cash dividend (the "Special Dividend") in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka") pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The Special Dividend, which ARCA estimates will be $1.59 per share of ARCA's common stock, will be payable in cash to th
- SECSEC Form 425 filed by ARCA biopharma Inc.425 - ARCA biopharma, Inc. (0000907654) (Subject)
ABIO FAQ
5 questionsWhat does ARCA biopharma Inc. do?
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart...Where does ABIO stock trade?
ARCA biopharma Inc. (ABIO) is listed on NASDAQ.What sector and industry is ABIO in?
ARCA biopharma Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What companies are similar to ABIO?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare ABIO side-by-side with any of them on Quantisnow.How can I track ABIO on Quantisnow?
Quantisnow aggregates ARCA biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABIO to receive live email and push alerts on every new disclosure.